Spinal Lamina Ii Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Taxonomy | ID | Name / Label |
|---|
Spinal Lamina II neurons, also known as the Substantia Gelatinosa, constitute a critical processing center within the dorsal horn of the spinal cord. These neurons play a fundamental role in modulating nociceptive (pain) transmission, sensory gating, and are increasingly recognized for their involvement in neurodegenerative disease processes affecting the central nervous system. [1]
Lamina II is situated in the superficial dorsal horn of the spinal cord, immediately dorsal to Lamina III. The region is characterized by a dense network of interneurons and glial cells, with a distinctive gelatinous appearance due to its high density of neuropil and relatively low cell body density. The substantia gelatinosa extends throughout the rostrocaudal axis of the spinal cord, with the highest concentration in cervical and lumbar enlargements corresponding to upper and lower limb innervation. [2]
The Lamina II neuronal population consists primarily of: [3]
| Marker | Expression | Significance | [4]
|--------|------------|--------------| [5]
| GAD67 | High | GABA synthesis enzyme |
| VGLUT2 | High | Vesicular glutamate transporter |
| PKCγ | Subset | Protein kinase C gamma isoform |
| Calretinin | Subset | Calcium binding protein |
| NPY | Subset | Neuropeptide Y |
Lamina II serves as the primary gateway for processing nociceptive (pain) information from peripheral nociceptors. The region receives input from Aδ and C fiber primary afferents that carry information about potentially tissue-damaging stimuli. Within Lamina II, these inputs undergo significant processing through complex synaptic interactions between excitatory and inhibitory interneurons.
The neuronal circuits within Lamina II perform several critical functions:
The substantia gelatinosa implements a "gate control" mechanism whereby:
Emerging evidence indicates Lamina II neurons also participate in itch sensation. Specific populations of interneurons expressing gastrin-releasing peptide (GRP) and its receptor (GRPR) are implicated in itch signaling, demonstrating the complex multiplexing of sensory modalities within this region.
While Lamina II is not traditionally considered a primary focus of Alzheimer's disease (AD) pathology, emerging research suggests several connections:
Lamina II involvement in Parkinson's disease (PD) relates to:
Lamina II may be affected in ALS through:
A key intersection between neurodegenerative diseases and Lamina II function is the development of chronic pain:
Several drug classes target Lamina II circuitry:
| Drug Class | Mechanism | Application |
|---|---|---|
| Gabapentinoids (gabapentin, pregabalin) | Bind to α2δ subunit of voltage-gated calcium channels | Neuropathic pain |
| Opioids | Activate μ-opioid receptors on interneurons | Severe pain |
| Baclofen | GABA-B receptor agonist | Spasticity, pain |
| SSRI/SNRIs | Enhance descending inhibition | Chronic pain |
Spinal Lamina Ii Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Spinal Lamina Ii Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Todd AJ. Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11(12):823-836. 2010. ↩︎
Kuner R. Central mechanisms of pathological pain. Nat Med. 2010;16(11):1258-1266. 2010. ↩︎
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895-926. 2009. ↩︎
Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-284. 2009. ↩︎
Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288(5472):1765-1768. 2000. ↩︎